16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Belgium’s largest drugmaker UCB today announced an update on its progress at its annual shareholder meeting (AGM), with the news edging its shares up 1.7% to 122.90 by midday. 25 April 2024
The US Food and Drug Administration (FDA) yesterday announced the approval of Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. 25 April 2024
San Diego, USA-based Travere Therapeutics and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for Filspari (sparsentan). 24 April 2024
Swiss pharma giant Roche first-quarter 2024 sales figures this morning that were disappointing in some respects and saw the firm’s shares fall 3.5% to 221.70 francs. 24 April 2024
Swiss pharma giant Novartis and the product development partnership Medicines for Malaria Venture (MMV) have announced positive data from their Phase II/III CALINA study. 24 April 2024
A single-line order from the US Supreme Court has scotched hopes on the part of Vanda Pharmaceuticals of resurrecting patents for Hetlioz (tasimelteon). 23 April 2024
Swiss pharma giant Novartis today raised its full-year guidance after reporting better-than-expected first-quarter 2024 results, with the firm’s shares rising as much as 4.8% in early trading. 23 April 2024
Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the US Medicare Drug Price Negotiation landscape, the top 20 global biopharmaceutical companies experienced a promising first quarter this year. 23 April 2024
Following a positive recommendation last month by the European Medicines Agency’s (EMA) human medicines committee (CHMP), today the European Commission (EC) granted marketing authorization for Emblaveo (aztreonam-avibactam) from Pfizer. 22 April 2024
Menarini Stemline has welcomed the publication of final draft guidance from the National Institute for Health and Care Excellence (NICE) recommending the use of Nexpovio (selinexor) alongside bortezomib and dexamethasone, for eligible multiple myeloma patients who have received one or two prior treatments. 22 April 2024
Japanese drug majors Takeda Pharmaceutical and Astellas Pharma, along with Sumitomo Mitsui Banking, today announced the signing of a master agreement to establish a joint venture company. 22 April 2024
The European Federation of pharmaceutical Industries Associations (EFPIA) and its members support the European Union (EU) leaders call for a new European Competitiveness Deal and call for a dedicated Health and Life Sciences Strategy as part of the wider strategy. 22 April 2024
The European Commission says it is inviting comments on commitments offered by Switzerland-based Vifor to address competition concerns over the alleged disparagement of its closest - and potentially only – competing treatment in Europe for intravenous iron treatment, Denmark’s Pharmacosmos' Monofer (iron isomaltoside). 22 April 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.